Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) rose 8.9% on Wednesday. The company traded as high as $7.83 and last traded at $8.1590. 308,627 shares were traded during mid-day trading, a decline of 82% from the average session volume of 1,742,524 shares. The stock had previously closed at $7.49.
Analyst Ratings Changes
A number of brokerages recently commented on KURA. Deutsche Bank set a $24.00 price target on Kura Oncology in a report on Wednesday, October 14th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. Raymond James Financial set a $24.00 target price on Kura Oncology in a research report on Monday, August 24th. Wedbush lifted their target price on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. initiated coverage on Kura Oncology in a research note on Thursday, October 1st. They issued an “overweight” rating and a $30.00 target price on the stock. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.88.
Check Out Our Latest Research Report on Kura Oncology
Kura Oncology Stock Performance
The company has a 50-day moving average of $9.95 and a 200 day moving average of $9.76. The firm has a market capitalization of $686.80 million, a PE ratio of -2.26 and a beta of 0.56. The company has a quick ratio of 3.56, a current ratio of 3.60 and a debt-to-equity ratio of 0.07.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.04. The company had revenue of $22.84 million during the quarter, compared to analyst estimates of $24.94 million. Kura Oncology had a negative return on equity of 336.24% and a negative net margin of 369.26%. Equities research analysts predict that Kura Oncology, Inc. will post -3.20 EPS for the current year.
Insider Activity
In other news, SVP Thomas Doyle sold 4,607 shares of Kura Oncology stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.50, for a total value of $48,373.50. Following the transaction, the senior vice president owned 142,428 shares in the company, valued at approximately $1,495,494. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $309,621.50. Following the completion of the sale, the insider owned 141,095 shares of the company’s stock, valued at $1,516,771.25. The trade was a 16.95% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have bought 300,000 shares of company stock worth $2,743,765 and have sold 122,394 shares worth $1,310,502. Corporate insiders own 7.60% of the company’s stock.
Hedge Funds Weigh In On Kura Oncology
Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Kura Oncology in the second quarter worth about $115,286,000. Dimensional Fund Advisors LP raised its position in Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after purchasing an additional 348,127 shares during the last quarter. Algert Global LLC bought a new position in Kura Oncology during the 3rd quarter valued at approximately $13,976,000. Bank of America Corp DE lifted its holdings in Kura Oncology by 46.1% in the 1st quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock worth $10,001,000 after buying an additional 388,003 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Kura Oncology in the 2nd quarter worth approximately $10,927,000.
Kura Oncology Company Profile
Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.
Recommended Stories
- Five stocks we like better than Kura Oncology
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
